The strongest evidence right now in where most of the FDA-approved machine learning devices are, are currently within radiology, the second really following radiation oncology, and the third being within pathology at this point in time. The things that I think are growing and will become more popular over time will be patient monitoring tools using artificial intelligence...
The strongest evidence right now in where most of the FDA-approved machine learning devices are, are currently within radiology, the second really following radiation oncology, and the third being within pathology at this point in time. The things that I think are growing and will become more popular over time will be patient monitoring tools using artificial intelligence. And then also tools like open evidence I think will become very, very crucial in terms of how our trainees, how our current workforce utilizes those things to help administer better care to patients. The way that I phrase it to individuals of that open evidence and other artificial platforms can elevate the level of care in areas that have struggled to have access to good clinical trials, good specialists as well too, that it can level the playing field and improve the care that’s delivered within community practices to the level of those within academic practices as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
